March Altus Capital Management as of June 30, 2015
Portfolio Holdings for March Altus Capital Management
March Altus Capital Management holds 20 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Universal Hlth Svcs CL B (UHS) | 12.1 | $2.1M | 15k | 142.13 | |
| United Therapeutics Corporation (UTHR) | 10.1 | $1.7M | 10k | 173.94 | |
| Eli Lilly & Co. (LLY) | 7.6 | $1.3M | 16k | 83.49 | |
| Dex (DXCM) | 7.2 | $1.2M | 16k | 79.98 | |
| Regeneron Pharmaceuticals (REGN) | 6.8 | $1.2M | 2.3k | 510.03 | |
| Alexion Pharmaceuticals | 6.2 | $1.1M | 5.9k | 180.70 | |
| Thoratec Corp Com New | 6.1 | $1.0M | 24k | 44.58 | |
| Cynosure Cl A | 5.7 | $983k | 26k | 38.59 | |
| Mallinckrodt Pub SHS | 5.6 | $963k | 8.2k | 117.77 | |
| CIGNA Corporation | 4.6 | $784k | 4.8k | 161.92 | |
| Humana (HUM) | 4.3 | $739k | 3.9k | 191.35 | |
| Zoetis Cl A (ZTS) | 4.2 | $721k | 15k | 48.21 | |
| AmerisourceBergen (COR) | 4.1 | $713k | 6.7k | 106.31 | |
| Zeltiq Aesthetics | 3.1 | $535k | 18k | 29.45 | |
| Receptos | 2.5 | $428k | 2.3k | 190.14 | |
| Seattle Genetics | 2.5 | $424k | 8.8k | 48.36 | |
| Neurocrine Biosciences (NBIX) | 2.4 | $410k | 8.6k | 47.71 | |
| Ultragenyx Pharmaceutical (RARE) | 2.0 | $338k | 3.3k | 102.46 | |
| Catalyst Pharmaceutical Partners (CPRX) | 1.9 | $334k | 81k | 4.13 | |
| Agenus Com New | 0.9 | $160k | 19k | 8.64 |
